The United States quantitative real-time polymerase chain reaction (qPCR) and digital PCR (dPCR) instrumentation markets are at different growth stages, yet both remain competitively dynamic. Despite its maturity, the low-growth qPCR market is witnessing a period of competitive expansion, as several big name life science tool companies entered the market looking to expand their genomics workflow solutions. Meanwhile, the emerging dPCR market is growing rapidly as implementation by early-adopters ramps up and suppliers expand the technology's applications to increase the scope for adoption.
New analysis from Frost & Sullivan's (lifesciences.frost.com) U.S. qPCR and dPCR Instrumentation Markets research finds the market earned revenue of more than $220.0 million in 2011 and estimates this to reach $310.0 million in 2016.
If you are interested in more information on this research, please email Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
The broad and growing range of applications enabled by or requiring qPCR makes the technology highly valuable and essential in many research laboratories.
"qPCR maintains an entrenched role in research due to its performance, sensitivity, and reproducibility, and, therefore, the market remains stable despite economic uncertainties," said Frost & Sullivan Life Sciences Senior Industry Analyst Christi Bird. "To expand the installed base in this nearly saturated market, several suppliers launched affordable, low-throughput qPCR benchtop platforms to encourage installation in individual laboratories."
Meanwhile, competitors in the budding dPCR market are working on new clinical uses to expand the value of the technology. As the number of dPCR applications grows beyond copy number variation, rare mutation detection, and absolute quantification of nucleic acid sequences, researchers are more likely to acknowledge the capabilities and advantages of dPCR surpass those of qPCR technology.
Due to the maturity of the qPCR market, the gap in terms of technology, instrument performance, and quality has narrowed among competitors. Manufacturers lowered prices to stay competitive, reducing the potential value of the market. Additionally, budget constraints in the United States academic sector continue to alter the purchasing cycle of new instruments, despite lowered qPCR pricing.
Meanwhile, pricing of dPCR instruments remains expensive as a new technology, as many laboratories find adoption cost-prohibitive. dPCR currently serves a limited customer segment including pharmaceutical and biotechnology companies, as well as large academic laboratories or core facilities with substantial capital equipment budgets.
"dPCR manufacturers must enhance instrument value well beyond qPCR capabilities for researchers to justify the hefty price tag," concluded Bird. "Several suppliers launched integrated dPCR and qPCR instruments to expand the applications that can be conducted on a single platform, hoping to drive greater product value."
U.S. qPCR and dPCR Instrumentation Markets is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Global Quantitative and dPCR Instrumentation and Consumables Purchasing Trends, Survey of Sequencing Technologies: Instrument Adoption on the Rise as Affordable Systems Enter the Market, and Purchasing Trends in the Research Antibodies Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation
U.S. qPCR and dPCR Instrumentation Markets / NB18-52